The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction

References

• Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819–837. doi:10.1016/j.cmet.2013.04.008
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 2016;4(6):525–536. doi:10.1016/S2213-8587(15)00482-9
   PubMed Web of Science ®Google Scholar
• Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Investig. 2010;1(1–2):8–23. doi:10.1111/j.2040-1124.2010.00022.x
   PubMed Web of Science ®Google Scholar
• Hasib A, Ng MT, Khan D, Gault VA, Flatt PR, Irwin N. A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice. Peptides. 2018;100:202–211. doi:10.1016/j.peptides.2017.10.015
   PubMed Web of Science ®Google Scholar
• Grill HJ. A role for GLP-1 in treating hyperphagia and obesity. Endocrinology. 2020;161(8):bqaa093. doi:10.1210/endocr/bqaa093
   Web of Science ®Google Scholar
• Williams DM, Nawaz A, Evans M. Drug therapy in obesity: a review of current and emerging treatments. Diabetes Ther. 2020;11(6):1199–1216. doi:10.1007/s13300-020-00816-y
   PubMed Web of Science ®Google Scholar
• Elahi D, McAloon-Dyke M, Fukagawa NK, et al. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7–37) in normal and diabetic subjects. Regul Pept. 1994;51(1):63–74. doi:10.1016/0167-0115(94)90136-8
   PubMedGoogle Scholar
• Holst JJ, Rosenkilde MM. Recent advances of GIP and future horizons. Peptides. 2020;125:170230. doi:10.1016/j.peptides.2019.170230
   Web of Science ®Google Scholar
• Yamada Y, Seino Y. Physiology of GIP–a lesson from GIP receptor knockout mice. Horm Metab Res. 2004;36(11–12):771–774. doi:10.1055/s-2004-826162
   Web of Science ®Google Scholar
• Kim SJ, Nian C, Karunakaran S, Clee SM, Isales CM, McIntosh CH. GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis. PLoS One. 2012;7(7):e40156. doi:10.1371/journal.pone.0040156
   PubMed Web of Science ®Google Scholar
• Holst JJ. The incretin system in healthy humans: the role of GIP and GLP-1. Metabolism. 2019;96:46–55. doi:10.1016/j.metabol.2019.04.014
   PubMed Web of Science ®Google Scholar
• Girard J. Glucagon, a key factor in the pathophysiology of type 2 diabetes. Biochimie. 2017;143:33–36. doi:10.1016/j.biochi.2017.10.004
   Web of Science ®Google Scholar
• Mathiesen DS, Bagger JI, Bergmann NC, et al. The effects of dual GLP-1/GIP receptor agonism on glucagon secretion-A review. Int J Mol Sci. 2019;20(17):4092. doi:10.3390/ijms20174092
   Web of Science ®Google Scholar
• Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102. doi:10.1016/j.molmet.2020.101102
   PubMed Web of Science ®Google Scholar
• Perez-Montes DE, Oca A, Pellitero S, Puig-Domingo M. Obesity and GLP-1. Minerva Endocrinol. 2021;46(2):168–176. doi:10.23736/S2724-6507.20.03369-6
   Web of Science ®Google Scholar
• Verma S, McGuire DK, Bain SC, et al. Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: results of the LEADER and SUSTAIN 6 trials. Diabetes Obes Metab. 2020;22(12):2487–2492. doi:10.1111/dom.14160
   PubMed Web of Science ®Google Scholar
• Bailey CJ. GIP analogues and the treatment of obesity-diabetes. Peptides. 2020;125:170202. doi:10.1016/j.peptides.2019.170202
   PubMed Web of Science ®Google Scholar
• Chia CW, Carlson OD, Kim W, et al. Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. Diabetes. 2009;58(6):1342–1349. doi:10.2337/db08-0958
   PubMed Web of Science ®Google Scholar
• Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3–14. doi:10.1016/j.molmet.2018.09.009
   PubMed Web of Science ®Google Scholar
• Min T, Bain SC. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS Clinical Trials. Diabetes Ther. 2021;12(1):143–157. doi:10.1007/s13300-020-00981-0
   PubMed Web of Science ®Google Scholar
• Finan B, Ma T, Ottaway N, et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med. 2013;5(209):209ra151. doi:10.1126/scitranslmed.3007218
   PubMed Web of Science ®Google Scholar
• Nørregaard PK, Deryabina MA, Tofteng Shelton P, et al. A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents. Diabetes Obes Metab. 2018;20(1):60–68. doi:10.1111/dom.13034
   PubMed Web of Science ®Google Scholar
• Frias JP, Bastyr EJ 3rd, Vignati L, et al. The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes. Cell Metab. 2017;26(2):343–352.e2. doi:10.1016/j.cmet.2017.07.011
   PubMed Web of Science ®Google Scholar
• Thomas MK, Nikooienejad A, Bray R, et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab. 2021;106(2):388–396. doi:10.1210/clinem/dgaa863
   PubMed Web of Science ®Google Scholar
• Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol Metab. 2020;31(6):410–421. doi:10.1016/j.tem.2020.02.006
   PubMed Web of Science ®Google Scholar
• Urva S, Coskun T, Loghin C, et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes Obes Metab. 2020;22(10):1886–1891. doi:10.1111/dom.14110
   PubMed Web of Science ®Google Scholar
• Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. doi:10.1172/jci.insight.140532
   PubMed Web of Science ®Google Scholar
• Hartman ML, Sanyal AJ, Loomba R, et al. Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care. 2020;43(6):1352–1355. doi:10.2337/dc19-1892
   PubMed Web of Science ®Google Scholar
• Usui R, Yabe D, Seino Y. Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity. J Diabetes Investig. 2019;10(4):902–905. doi:10.1111/jdi.13005
   PubMed Web of Science ®Google Scholar
• Andrikou E, Tsioufis C, Andrikou I, Leontsinis I, Tousoulis D, Papanas N. GLP-1 receptor agonists and cardiovascular outcome trials: an update. Hellenic J Cardiol. 2019;60(6):347–351. doi:10.1016/j.hjc.2018.11.008
   Web of Science ®Google Scholar
• Sheahan KH, Wahlberg EA, Gilbert MP. An overview of GLP-1 agonists and recent cardiovascular outcomes trials. Postgrad Med J. 2020;96(1133):156–161. doi:10.1136/postgradmedj-2019-137186
   PubMed Web of Science ®Google Scholar
• Mori Y, Matsui T, Hirano T, Yamagishi SI. GIP as a potential therapeutic target for atherosclerotic cardiovascular disease-a systematic review. Int J Mol Sci. 2020;21(4):1509. doi:10.3390/ijms21041509
   Web of Science ®Google Scholar
• Rao Kondapally Seshasai S, Kaptoge S, Thompson A, et al. Emerging risk factors collaboration. diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829–841. Erratum in: N Engl J Med. 2011;364(13):1281.
   PubMed Web of Science ®Google Scholar
• Gimeno Orna JA, Ortez Toro JJ, Peteiro Miranda CM. Evaluation and management of residual cardiovascular risk in patients with diabetes. Endocrinol Diabetes Nutr. 2020;67(4):279–288. doi:10.1016/j.endinu.2019.05.004
   Web of Science ®Google Scholar
• Seino Y, Yabe D. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: incretin actions beyond the pancreas. J Diabet Investig. 2013;4:108–130.
   PubMed Web of Science ®Google Scholar
• Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia. 2002;45(8):1111–1119. doi:10.1007/s00125-002-0878-6
   PubMed Web of Science ®Google Scholar
• Vilsbøll T, Knop FK, Krarup T, et al. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. J Clin Endocrinol Metab. 2003;88(10):4897–4903. doi:10.1210/jc.2003-030738
   PubMed Web of Science ®Google Scholar
• Nasteska D, Harada N, Suzuki K, et al. Chronic reduction of GIP secretion alleviates obesity and insulin resistance under high-fat diet conditions. Diabetes. 2014;63(7):2332–2343. doi:10.2337/db13-1563
   PubMed Web of Science ®Google Scholar
• Nakamura T, Tanimoto H, Mizuno Y, et al. Gastric inhibitory polypeptide receptor antagonist, SKL-14959, suppressed body weight gain on diet-induced obesity mice. Obes Sci Pract. 2018;4(2):194–203. doi:10.1002/osp4.164
   PubMed Web of Science ®Google Scholar
• NamKoong C, Kim MS, Jang BT, Lee YH, Cho YM, Choi HJ. Central administration of GLP-1 and GIP decreases feeding in mice. Biochem Biophys Res Commun. 2017;490(2):247–252. doi:10.1016/j.bbrc.2017.06.031
   PubMed Web of Science ®Google Scholar
• Mroz PA, Finan B, Gelfanov V, et al. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism. Mol Metab. 2019;20:51–62. doi:10.1016/j.molmet.2018.12.001
   PubMed Web of Science ®Google Scholar
• Adriaenssens AE, Biggs EK, Darwish T, et al. Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake. Cell Metab. 2019;30(5):987–996.e6. doi:10.1016/j.cmet.2019.07.013
   PubMed Web of Science ®Google Scholar
• Harikumar KG, Wootten D, Pinon DI, et al. Glucagon-like peptide-1 receptor dimerization differentially regulates agonist signaling but does not affect small molecule allostery. Proc Natl Acad Sci U S A. 2012;109(45):18607–18612. doi:10.1073/pnas.1205227109
   PubMed Web of Science ®Google Scholar
• Wilson JM, Lin Y, Luo MJ, et al. The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: a post hoc analysis. Diabetes Obes Metab. 2022;24(1):148–153. doi:10.1111/dom.14553
   PubMed Web of Science ®Google Scholar
• Farah C, Michel LYM, Balligand JL. Nitric oxide signalling in cardiovascular health and disease. Nat Rev Cardiol. 2018;15(5):292–316. doi:10.1038/nrcardio.2017.224
   PubMed Web of Science ®Google Scholar
• Zhong Q, Bollag RJ, Dransfield DT, et al. Glucose-dependent insulinotropic peptide signaling pathways in endothelial cells. Peptides. 2000;21(9):1427–1432. doi:10.1016/S0196-9781(00)00287-4
   Web of Science ®Google Scholar
• Tahara N, Tahara A, Honda A, et al. Molecular imaging of vascular inflammation. Curr Pharm Des. 2014;20(14):2439–2447. doi:10.2174/13816128113199990479
   Web of Science ®Google Scholar
• Chinetti-Gbaguidi G, Colin S, Staels B. Macrophage subsets in atherosclerosis. Nat Rev Cardiol. 2015;12(1):10–17. doi:10.1038/nrcardio.2014.173
   PubMed Web of Science ®Google Scholar
• Chistiakov DA, Bobryshev YV, Orekhov AN. Macrophage-mediated cholesterol handling in atherosclerosis. J Cell Mol Med. 2016;20(1):17–28. doi:10.1111/jcmm.12689
   PubMed Web of Science ®Google Scholar
• Nagashima M, Watanabe T, Terasaki M, et al. Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice. Diabetologia. 2011;54(10):2649–2659. doi:10.1007/s00125-011-2241-2
   PubMed Web of Science ®Google Scholar
• Kahles F, Liberman A, Halim C, et al. The incretin hormone GIP is upregulated in patients with atherosclerosis and stabilizes plaques in ApoE-/- mice by blocking monocyte/macrophage activation. Mol Metab. 2018;14:150–157. doi:10.1016/j.molmet.2018.05.014
   Web of Science ®Google Scholar
• Mori Y, Kushima H, Koshibu M, et al. Glucose-dependent insulinotropic polypeptide suppresses peripheral arterial remodeling in male mice. Endocrinology. 2018;159(7):2717–2732. doi:10.1210/en.2018-00336
   Web of Science ®Google Scholar
• Hiromura M, Mori Y, Kohashi K, et al. Suppressive effects of glucose-dependent insulinotropic polypeptide on cardiac hypertrophy and fibrosis in angiotensin II-infused mouse models. Circ J. 2016;80(9):1988–1997. doi:10.1253/circj.CJ-16-0152
   PubMed Web of Science ®Google Scholar
• Ussher JR, Campbell JE, Mulvihill EE, et al. Inactivation of the glucose-dependent insulinotropic polypeptide receptor improves outcomes following experimental myocardial infarction. Cell Metab. 2018;27(2):450–460.e6. doi:10.1016/j.cmet.2017.11.003
   PubMed Web of Science ®Google Scholar
• Ben-Shlomo S, Zvibel I, Varol C, et al. Role of glucose-dependent insulinotropic polypeptide in adipose tissue inflammation of dipeptidylpeptidase 4-deficient rats. Obesity. 2013;21(11):2331–2341. doi:10.1002/oby.20340
   Web of Science ®Google Scholar
• Varol C, Zvibel I, Spektor L, et al. Long-acting glucose-dependent insulinotropic polypeptide ameliorates obesity-induced adipose tissue inflammation. J Immunol. 2014;193(8):4002–4009. doi:10.4049/jimmunol.1401149
   Web of Science ®Google Scholar
• Chen S, Okahara F, Osaki N, Shimotoyodome A. Increased GIP signaling induces adipose inflammation via a HIF-1α-dependent pathway and impairs insulin sensitivity in mice. Am J Physiol Endocrinol Metab. 2015;308(5):E414–25. doi:10.1152/ajpendo.00418.2014
   Web of Science ®Google Scholar
• Suzuki Y, Nakamura N, Miyabe M, et al. Anti-inflammatory role of glucose-dependent insulinotropic polypeptide in periodontitis. J Diabetes Investig. 2016;7(4):497–505. doi:10.1111/jdi.12450
   Web of Science ®Google Scholar
• Weaver RE, Donnelly D, Wabitsch M, Grant PJ, Balmforth AJ. Functional expression of glucose-dependent insulinotropic polypeptide receptors is coupled to differentiation in a human adipocyte model. Int J Obes. 2008;32(11):1705–1711. doi:10.1038/ijo.2008.148
   Web of Science ®Google Scholar
• Szalowska E, Meijer K, Kloosterhuis N, Razaee F, Priebe M, Vonk RJ. Sub-chronic administration of stable GIP analog in mice decreases serum LPL activity and body weight. Peptides. 2011;32(5):938–945. doi:10.1016/j.peptides.2011.02.011
   Web of Science ®Google Scholar
• Nogi Y, Nagashima M, Terasaki M, Nohtomi K, Watanabe T, Hirano T. Glucose-dependent insulinotropic polypeptide prevents the progression of macrophage-driven atherosclerosis in diabetic apolipoprotein E-null mice. PLoS One. 2012;7(4):e35683. doi:10.1371/journal.pone.0035683
   Web of Science ®Google Scholar
• Thompson A, Kanamarlapudi V. Type 2 Diabetes Mellitus and Glucagon Like Peptide-1 Receptor Signalling. Clin Exp Pharmacol. 2013;3:4.
   Google Scholar